Sunitha Lakshminarayanan

Sunitha is a seasoned executive with over 20 years of experience and brings to Actinium broad-based technical expertise across biologics, biosimilars, vaccines, and cell/gene therapy products. Prior to joining Actinium, Sunitha was at Bristol-Myers Squibb in their Cell Therapy division, most recently as Executive Director, Global Process Engineering. During her tenure at Celgene/BMS, she was responsible for the global licensure of their two autologous cell therapy products, Breyanzi® and Abecma®. Post-approval, she built the teams that provided support for commercial products. She was also responsible for new cell therapy facility build-outs for network expansions, technology transfers, product life-cycle management, new technology commercialization, comparability, and Global MS&T labs. Prior to BMS, Sunitha was at Kashiv BioSciences where she built the process development and technical services teams, led filing activities, and obtained approvals for Releuko® and Fylnetra®. Prior to Kashiv, Sunitha held various leadership positions at Progenics Pharmaceuticals, Laureate Pharma, and BioReliance. Sunitha earned her MBA from Northwestern University, her Master's in Chemical Engineering from Penn State University, and her BS in Chemical Engineering from the Coimbatore Institute of Technology, India.